Su principal funcion es prevenir en mayor o menor grado los sintomas derivados de la anormal estimulacion del laberinto. Nombre de los medicamentos: Genérico y Comercial – Aprenda acerca de las causas, los síntomas, el diagnóstico y el tratamiento de los Manuales MSD. La Primer Guia Online de Medicamentos Argentinos ARGENTINA S.A., , , , ANTIVERTIGINOSO. BETASERC 16 mg comp.x 30 ARGENTINA S.A., , , ANTIVERTIGINOSO. BETASERC 24 mg.

Author: Juzragore Sasho
Country: Comoros
Language: English (Spanish)
Genre: Science
Published (Last): 7 June 2008
Pages: 147
PDF File Size: 2.55 Mb
ePub File Size: 16.99 Mb
ISBN: 967-6-48178-953-5
Downloads: 52641
Price: Free* [*Free Regsitration Required]
Uploader: Arashitaur

Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Cancer AND drug name.

Pneumonia AND sponsor name. Antivertigiosos to search [pdf]. For these items you should use the filters and not add them to your search terms in the text field. Trials with results Trials without results Clear advanced search filters.



Review by the Competent Authority or Ethics Committee in the country concerned. EU Clinical Trials Register.

Both Female Only Male Only. IMP with orphan designation in the indication.

Ciclizina – Wikipédia, a enciclopédia livre

Trials with results Trials without results. Clear advanced search filters.

Date on which this record was first entered in the EudraCT database:. Estudio doble ciego, controlado con placebo sobre la eficacia y tolerancia de V 1g, medicamengos y 4g en neuritis vestibular A double-blind placebo controlled study of 1g, 2g and 4g V efficacy and tolerance in vestibular neuritis. The IMP has been designated in this indication as an orphan drug in the Community.

Indice multientrada – Farmanuario

Ajtivertiginosos on Advanced therapies CAT has issued a classification for this product. Combination product that includes a device, but does not involve an Advanced Therapy.

V is a new investigational antivertiginous agent which is being developed for the treatment of symptomatic vertiginous crisis. The trial involves medicamdntos site in the Member State concerned. Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial.